AUA Guideline for the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Hanno, Philip M.; Burks, David; Clemens, J. Quentin; Dmochowski, Roger R.; Erickson, Deborah; FitzGerald, Mary P.; Forrest, John B.; Gordon, Bárbara; Gray, Mikel; Mayer, Robert; Newman, Diane K.; Nyberg, Leroy; Payne, Christopher K.; Wesselmann, Ursula; Faraday, Martha M.

doi:10.1016/j.juro.2011.03.064

Cited by 588 publications

(561 citation statements)

References 36 publications

Supporting

Mentioning

540

Contrasting

Unclassified

Order By: Relevance

“…Das japanische Interstitial Cystitis Guideline Committee beschreibt die Technik der Hydrodistension wie folgt: Unter Spinalanästhesie Füllung der Blase bis 80 cm H2O Druck unter ständiger zystoskopischer Kontrolle bis max 800 -1000 ml und Ablassen der Fül-lung unter optischer Kontrolle [6]. Die AUA Guidelines empfehlen eine Niedrigdruckdistension die 3 malig in dem Eingriff sequentiell wiederholt wird [7]. Eine Hochdruckdistension von mehr als 10 Minuten mit über 80 cm H2O und mehr wird explizit nicht empfohlen [7].…”

unclassified

See 1 more Smart Citation

Hydrodistension der Harnblase zur Diagnostik und Therapie

Kaftan

Wiedemann

2018

Aktuel Urol

View full text Add to dashboard Cite

unclassified

“…Die AUA Guidelines empfehlen eine Niedrigdruckdistension die 3 malig in dem Eingriff sequentiell wiederholt wird [7]. Eine Hochdruckdistension von mehr als 10 Minuten mit über 80 cm H2O und mehr wird explizit nicht empfohlen [7]. …”

unclassified

Hydrodistension der Harnblase zur Diagnostik und Therapie

Kaftan

Wiedemann

2018

Aktuel Urol

View full text Add to dashboard Cite

“…Definition criteria for the disease are still not uniform worldwide despite some progress. [5][6][7] Large multicentric randomized trials are warranted, as existing studies are either not placebo controlled or of a small scale.…”

Section: Editorial Comment Editorial Comment From Professor Dinis To mentioning

confidence: 99%

Editorial Comment from Dr Yoshimura to Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis

Yoshimura

2014

Int J of Urology

View full text Add to dashboard Cite

This Review Article by Jhang well summarizes the recent advancement for the use of intravesical botulinum toxin injection for the treatment of bladder pain syndrome/interstitial cystitis, as well as the potential mechanisms underlying the therapeutic efficacy of the botulinum toxin treatment, such as peripheral desensitization, reduction of apoptotic changes in urothelial cells and suppression of bladder inflammation. Although some studies showed therapeutic efficacy of botulinum toxin for bladder pain, frequency, bladder capacity and symptom score in bladder pain syndrome/interstitial cystitis patients, larger-sized, randomized trials with a placebo control are definitely required to confirm the efficacy. Also, the methods of botulinum toxin treatment including dosage, injection site/number and treatment interval vary among studies, and need to be standardized.

show abstract

“…Painful bladder syndrome/interstitial cystitis (PBS/IC) is a chronic syndrome that affects the lower urinary tract and which diagnosis is based on urinary symptoms and chronic pelvic pain or discomfort related to the bladder (1). Its aetiopathology is not fully known, but it is believed that the glycosaminoglycans (GAGs) and proteoglycans (PGs) that line the bladder urothelium can actively participate in its genesis.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis

et al. 2014

View full text Add to dashboard Cite

ARTICLE INFO ______________________________________________________________ ______________________Introduction: Painful bladder syndrome/interstitial cystitis (PBS/IC) pathogenesis is not fully known, but evidence shows that glycosaminoglycans (GAG) of bladder urothelium can participate in its genesis. The loss of these compounds facilitates the contact of urine compounds with deeper portions of bladder wall triggering an inflammatory process. We investigated GAG in urine and tissue of PBS/IC and pure stress urinary incontinence (SUI) patients to better understand its metabolism. Materials and Methods: Tissue and urine of 11 patients with PBS/IC according to NIDDK criteria were compared to 11 SUI patients. Tissue samples were analyzed by histological, immunohistochemistry and immunofluorescence methods. Statistical analysis were performed using t Student test and Anova, considering significant when p < 0.05. Results: PBS/IC patients had lower concentration of GAG in urine when compared to SUI (respectively 0.45 ± 0.11 x 0.62 ± 0.13 mg/mg creatinine, p < 0.05). However, there was no reduction of the content of GAG in the urothelium of both groups. Immunofluorescence showed that PBS/IC patients had a stronger staining of TGF-beta, decorin (a proteoglycan of chondroitin/dermatan sulfate), fibronectin and hyaluronic acid. Conclusion: the results suggest that GAG may be related to the ongoing process of inflammation and remodeling of the dysfunctional urothelium that is present in the PBS/IC.

show abstract

AUA Guideline for the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Cited by 588 publications

References 36 publications

Hydrodistension der Harnblase zur Diagnostik und Therapie

Hydrodistension der Harnblase zur Diagnostik und Therapie

Editorial Comment from Dr Yoshimura to Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis

Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis

Contact Info

Product

Resources

About